Swedbank AB Grows Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Swedbank AB lifted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 3.4% during the 4th quarter, HoldingsChannel.com reports. The fund owned 55,532 shares of the biopharmaceutical company’s stock after purchasing an additional 1,803 shares during the quarter. Swedbank AB’s holdings in Alnylam Pharmaceuticals were worth $13,067,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Huntington National Bank boosted its position in shares of Alnylam Pharmaceuticals by 91.8% during the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 45 shares during the period. SYM FINANCIAL Corp boosted its holdings in Alnylam Pharmaceuticals by 6.2% during the 3rd quarter. SYM FINANCIAL Corp now owns 947 shares of the biopharmaceutical company’s stock valued at $260,000 after acquiring an additional 55 shares during the period. Lindbrook Capital LLC grew its position in Alnylam Pharmaceuticals by 11.1% in the 3rd quarter. Lindbrook Capital LLC now owns 570 shares of the biopharmaceutical company’s stock valued at $157,000 after acquiring an additional 57 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its stake in Alnylam Pharmaceuticals by 0.9% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 6,512 shares of the biopharmaceutical company’s stock worth $1,532,000 after purchasing an additional 58 shares during the period. Finally, Harbor Capital Advisors Inc. lifted its position in shares of Alnylam Pharmaceuticals by 2.4% during the fourth quarter. Harbor Capital Advisors Inc. now owns 2,650 shares of the biopharmaceutical company’s stock worth $624,000 after purchasing an additional 63 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Analysts Set New Price Targets

ALNY has been the subject of a number of research reports. Cantor Fitzgerald restated a “neutral” rating and issued a $220.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, October 11th. William Blair reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Tuesday, November 19th. Royal Bank of Canada reiterated an “outperform” rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a report on Tuesday, January 21st. Barclays upped their price target on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a report on Friday, November 1st. Finally, Canaccord Genuity Group boosted their price objective on Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the stock a “buy” rating in a research report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $298.61.

Alnylam Pharmaceuticals Stock Down 2.1 %

Alnylam Pharmaceuticals stock opened at $271.31 on Friday. The stock has a 50-day simple moving average of $250.55 and a 200-day simple moving average of $260.87. The company has a market capitalization of $34.99 billion, a P/E ratio of -103.55 and a beta of 0.34. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The business had revenue of $500.90 million during the quarter, compared to the consensus estimate of $532.91 million. The company’s revenue was down 33.3% compared to the same quarter last year. During the same period in the prior year, the company posted $1.15 EPS. Equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.24 earnings per share for the current year.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Tolga Tanguler sold 1,469 shares of the stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $368,689.62. Following the completion of the sale, the executive vice president now directly owns 13,191 shares of the company’s stock, valued at approximately $3,310,677.18. This trade represents a 10.02 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Yvonne Greenstreet sold 5,219 shares of the business’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $1,309,864.62. Following the completion of the transaction, the chief executive officer now directly owns 78,880 shares in the company, valued at approximately $19,797,302.40. The trade was a 6.21 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 73,964 shares of company stock worth $20,622,925 in the last 90 days. 1.50% of the stock is owned by insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.